# US 2026/0234613 A1 · Nucleic acid ligand and conjugate thereof, and preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234613 A1
- Document ID: US20260234613A1
- Status: Published application
- Kind: A1
- Application number: 18/576,088
- Filed: 2022-07-01
- Published: 2026-08-13
- Earliest claimed: 2021-07-02
- Assignees: Tuojie Biotech (Shanghai) Co., Ltd.
- Applicants: Tuojie Biotech (Shanghai) Co., Ltd.
- Inventors: Jinyu Huang; Min Luo; Ke Yin; Zhe Hou; Yunfei Li
- Web page: https://patentgrep.com/patent/US20260234613A1

## CPC

- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07H 15/18: Acyclic radicals, substituted by carbocyclic rings
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

A nucleic acid ligand and a conjugate thereof, and a preparation method therefor and the use thereof. Specifically, provided is a ligand having the structure as represented by formula (I). The provided ligand achieves a good expression inhibition effect by means of the conjugation with a nucleic acid.

## Claims

### Claim 1

A ligand having a structure represented by formula (I),
wherein L1 is L3 or L3-R10—R11-L3, wherein L3 is independently a C1-C12 alkyl chain, —(CH2)j1—C(═O)—(CH2)j2— or —(CH2)j3—(CH2CH2O)1-4—(CH2)j4—; R10 and R11 are independently chemical bonds, —NR12—, —C(═O)— or —OC(═O)—; R12 is hydrogen or C1-C12 alkyl; j1, j2, j3 and j4 are independently integers of 0-10;
R1 and R2 are independently chemical bonds, —NR6—, —C(═O)— or —OC(═O)—;
R3 is independently CR7R8, NR6, O or S;
R4 is independently CR9 or N;
R5 is independently CR7R8, NR6 or O;
R6 and R9 are independently hydrogen, deuterium, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, SR′, S(═O)R′, S(═O)2R′, S(═O)2NR′(R″), NR′(R″), C(═O)R′, C(═O)OR′ or C(═O)NR′(R″), wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups selected from the group consisting of halogen, hydroxy, oxo, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C3-7 cycloalkyl, 3-12 membered heterocyclyl, 5-12 membered aryl, 5-12 membered heteroaryl, SR′, S(═O)R′, S(═O)2R′, S(═O)2NR′(R″), NR′(R″), C(═O)R′, C(═O)OR′ and C(═O)NR′(R″);
R7 and R8 are independently hydrogen, deuterium, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, SR′, S(═O)R′, S(═O)2R′, S(═O)2NR′(R″), NR′(R″), C(═O)R′, C(═O)OR′ or C(═O)NR′(R″), wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups selected from the group consisting of halogen, hydroxy, oxo, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C3-7 cycloalkyl, 3-12 membered heterocyclyl, 5-12 membered aryl, 5-12 membered heteroaryl, SR′, S(═O)R′, S(═O)2R′, S(═O)2NR′(R″), NR′(R″), C(═O)R′, C(═O)OR′ and C(═O)NR′(R″);
R′ and R″ are independently hydrogen, deuterium, hydroxy, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, oxo, nitro and cyano;
m, n, p and q are independently 0, 1, 2, 3 or 4;
B is
Rb1, Rb2, Rb3, Rb4, Rb5, Rb6 and Rb7 are independently —C(═O)—, —NHC(═O)—, —C(═O)O—, —C(═O)—(CH2)z8—O— or —NHC(═O)—(CH2)z9—O—;
z1, z2, z3, z4, z5, z6, z7, z8 and z9 are independently integers of 0-10;
L2 is L4 or L4-R13—R14-L4, wherein L4 is independently a C1-C12 alkyl chain or —(CH2)j5—(OCH2CH2)1-4—(CH2)j6—; R13 and R14 are independently chemical bonds, —NR15—, —C(═O)— or —OC(═O)—; R15 is independently hydrogen or C1-C12 alkyl; j5 and j6 are independently integers of 0-10;
r is an integer of 1-10.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The ligand according to claim 1, wherein
L1 is
wherein the end a1 is attached to B, and the end b1 is attached to R1.

### Claim 4 (depends on 1)

The ligand according to claim 1, wherein R1 and R2 are of any of the following combinations:
combination 1: R1 is a chemical bond and R2 is C═O;
combination 2: R1 is a chemical bond and R2 is NR6;
combination 3: R1 is a chemical bond and R2 is —OC(═O)—;
combination 4: R1 is NR6 and R2 is C═O;
combination 5: R1 is NR6 and R2 is —OC(═O)—;
combination 6: R2 is NR6 and R1 is C═O; and
combination 7: R2 is NR6 and R1 is —OC(═O)—.

### Claim 5 (depends on 1)

The ligand according to claim 1, wherein R6 is hydrogen or C1-6 alkyl;
and/or, R7 and R8 are hydrogen;
and/or, R9 is hydrogen.

### Claim 6 (depends on 1)

The ligand according to claim 1, wherein m is 0 or 1.

### Claim 7 (depends on 1)

The ligand according to claim 1, wherein p and q may be of any of the following combinations:
combination 1: p=1 and q=1;
combination 2: p=1 and q=0;
combination 3: p=0 and q=1; and
combination 4: p=0 and q=0.

### Claim 8 (depends on 1)

The ligand according to claim 1, wherein
B is
Rb1, Rb2, Rb3, Rb4, Rb5, Rb6 and Rb7 are independently —C(═O)— or —NHC(═O)—; the N atom of the end a2 is attached to L1;
preferably, B is

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The ligand according to claim 1, wherein
L2 is
wherein the end a3 is attached to O, and the end b3 is attached to B.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The ligand according to claim 1, wherein
is
preferably
and more preferably

### Claim 14 (depends on 1)

The ligand according to claim 1, wherein
preferably
more preferably
and further preferably

### Claim 15 (depends on 1)

The ligand according to claim 1, wherein the ligand is any of the following structures:

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A compound represented by formula (II),
wherein X is a hydroxy protecting group;
Y is hydrogen, deuterium,
j7 is 1, 2, 3 or 4;
W is a macromolecular compound;
L1, R1, R2, Q, B, L2, m, p, q and r are as defined in claim 1.

### Claim 18 (depends on 1, 17)

The compound according to claim 17, being a compound represented by formula (II-1), (II-2) or (II-3),
wherein
is resin;
L1, R1, R2, B, L2, m, p, q and r are as defined in claim 1.

### Claim 19

(canceled)

### Claim 20 (depends on 17)

The compound according to claim 17, being any of the following structures:
wherein Y is hydrogen or
or, Y is
wherein
is resin.

### Claim 21 (depends on 1)

A nucleic acid-ligand conjugate comprising a nucleic acid and one or more ligands according to claim 1, wherein the ligands are conjugated to an end of the nucleic acid, and the ligands are identical or different.

### Claim 22 (depends on 21)

The nucleic acid-ligand conjugate according to claim 21, wherein the nucleic acid and the ligands are linked by phosphoester groups, phosphorothioate groups or phosphonic acid groups;
and/or, the 3′ end of the nucleic acid is conjugated to the ligand;
and/or, the nucleic acid is a single-stranded nucleic acid, preferably the sense strand of an siRNA.

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The nucleic acid-ligand conjugate according to claim 21, wherein the nucleic acid-ligand conjugate is any of the following structures or a pharmaceutically acceptable salt thereof:
wherein
represents the nucleic acid.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 21)

A composition comprising the nucleic acid-ligand conjugate according to claim 21, and one or more pharmaceutically acceptable excipients.

### Claim 28

(canceled)

### Claim 29 (depends on 21)

A method for inhibiting mRNA expression in a patient or delivering an expression-inhibiting oligomeric compound to the liver in vivo, comprising administering to the patient the nucleic acid-ligand conjugate according to claim 21.

### Claim 30

(canceled)
